Previous 10 | Next 10 |
Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...
BELTSVILLE, Md., Oct. 02, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the promotion ...
BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical ...
Gainers: LATAM Airlines Group (NYSE: LTM ) +30% . Just Energy Group (NYSE: JE ) +26% . Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ) +20% . Tiziana Life Sciences PLC (NASDAQ: TLSA ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +14% . Ra Medical Systems, Inc. (NYSE: R...
The following slide deck was published by NextCure, Inc. in conjunction with this Read more ...
BELTSVILLE, Md., Sept. 03, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company w...
NextCure (NASDAQ: NXTC ): Q2 GAAP EPS of -$0.61 misses by $0.14 . More news on: NextCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BELTSVILLE, Md., Aug. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 201...
Artelo Biosciences (NASDAQ: ARTL ) initiated with Buy rating and $8 (113% upside) price target at Maxim Group. More news on: Artelo Biosciences, Inc., NextCure, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
NextCure (NASDAQ: NXTC ): Q1 GAAP EPS of -$4.46. More news on: NextCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...